Thrombus Migration After Tenecteplase Versus Alteplase in Acute Large Vessel Occlusion

What this is

Is a mechanical thrombectomy more effective when preceded by IV thrombolysis — and does the choice of thrombolytic change what happens to the clot before the retriever arrives? This large Chinese multicenter cohort asked a more granular version of that question: not “tenecteplase or alteplase, which is better overall,” but what the two drugs do to thrombus dynamics in the minutes before puncture. In 746 propensity-matched LVO patients, tenecteplase moved the clot nearly twice as often as alteplase (19.3% vs 11.3%), and — the mechanistic punchline — did so almost entirely within the first hour after the bolus. Critically, that migration was good: it was independently associated with 3-month functional independence (OR 1.62), driven by early reperfusion (mTICI 2b–3 before MT in 39.5% of migrants vs 8.7% of stable clots). The stroke field has spent a decade arguing whether bridging thrombolysis helps at all; this paper reframes the debate from “whether” to “how fast, and with what.”

1. Shadow Audit

The clean headline obscures a more equivocal interior. The “time-limited advantage” framing rests on a single interaction P-value of 0.043 — just past the 0.05 threshold and the least stable kind of evidence. And in the ≥60-minute stratum, tenecteplase did not lose: migration was 19.7% vs 15.0%, OR 1.39, merely non-significant (P = 0.204). That is very plausibly an underpowered stratum, not a biological cliff. The paper leans on “tenecteplase is largely cleared within 1 hour, so its advantage ends” — elegant pharmacokinetics — but the ≥60-minute numbers contradict the clean “convergence” story. The second shadow: migration cut complete reperfusion (mTICI 3) nearly in half (40.4% vs 68.8%). The authors reframe this as acceptable because antegrade flow was restored in proximal territory, but 39 of 114 migrants had outright technical failures. A skeptic’s reading: tenecteplase trades clean complete reperfusion for messy early partial reperfusion, and the favorable net outcome depends on early reperfusion saving more penumbra than the lost mTICI 3 costs.

2. Inversion Engine

For the opposite conclusion — that tenecteplase’s migration effect is clinically irrelevant or even harmful — to hold, several things would have to be true. First, the 3.77-fold excess migration in the <60-minute window (18.6% vs 6.2%, n ≈ 150–200 in that stratum) would have to be a selection artifact; given the near-perfect covariate balance (SMD ≤0.10) and κ = 0.851 image adjudication, the burden of proof is high. Second, the migration→functional-independence link (OR 1.62) would have to reverse in a direction the paper’s own multivariable model resists. To flip the practical recommendation, you would need the ~8-percentage-point functional-independence gain (OR 1.43) to be driven entirely by unmeasured confounding — implausible given adjustment, but the confidence interval (1.04–1.95) is wide enough that a modest truth is fully consistent. The cheapest falsification is a prospective randomized image-substudy of the ongoing NCT06658197; absent that, the point estimates are remarkably consistent with the AcT secondary analysis and the T-FLAVOR signal already in this corpus.

3. Second-Order Catalyst

The first mover is the high-volume LVO center with a <60-minute door-to-puncture capability. This paper gives a mechanism and a number to a practice that is already propagating — tenecteplase as the single-bolus bridging agent — and it sharpens the workflow implication: if migration (and therefore early reperfusion benefit) concentrates in the first hour, the angiography suite should be waiting for the bolus, not the other way around. The protocol change that moves tomorrow is simple: adopt 0.25 mg/kg tenecteplase as the default bridging thrombolytic at EVT-capable centers and compress the IVT-to-puncture interval, because that is precisely the window where the tenecteplase advantage lives and where alteplase’s slower lysis has not yet caught up. Chinese centers that switched after the 2023 Class IA guidance are already ahead; Western systems still on alteplase for pre-EVT bridging are the laggards.

4. Asymmetric Leverage

This is a small-effect, large-denominator story. The absolute migration difference was 8 percentage points (19.3% vs 11.3%), and the functional-independence gain was similar magnitude — OR ~1.4, roughly an 8–10% absolute shift. But the denominator is enormous: LVO stroke is one of the most common disabling emergencies in neurology, and essentially every patient goes through thrombolysis-before-thrombectomy decisions daily. A modest per-patient improvement multiplied across hundreds of thousands of procedures worldwide dwarfs the small effect sizes typical of neuro-protective trials. The genuinely asymmetric payoff, though, is temporal: the entire tenecteplase advantage is squandered past 60 minutes. A center that cuts IVT-to-puncture from 80 to 55 minutes captures leverage that a center with a perfect drug but a slow suite simply leaves on the table. The cheapest high-yield intervention is not a new drug — it’s workflow.

5. Paradigm Destroyer

The reflex this kills is “alteplase is fine for bridging because both agents are non-inferior.” Non-inferiority trials (ATTEST-2, AcT, and the JX10/ETLAS work in this corpus) established that tenecteplase is at least as good overall — but this paper shows the two drugs are mechanistically unequal in the window that matters most: the first hour before EVT, where the single-bolus tenecteplase dose produces an early lytic peak alteplase’s slow infusion cannot match. The two-sentence update: For LVO patients presenting to an EVT-capable center, give 0.25 mg/kg tenecteplase as the bridging bolus and aim for groin puncture within 60 minutes — that hour is where the drug earns its keep. The corollary that would update a call schedule: stop treating the thrombolytic as a fixed ritual and start treating IVT-to-puncture as a performance metric, because it is now mechanistically linked to which drug’s benefit you actually realize.

MVP — Minimum Viable Proof

The single clinical assertion that would change bedside practice if confirmed: In LVO patients, IVT-to-puncture time ≤60 minutes with tenecteplase yields a rate of thrombolysis-induced thrombus migration and early reperfusion high enough to raise 3-month independent functional outcome by roughly 8 absolute percentage points with no added sICH. If a prospective substudy of NCT06658197 (or the pooled randomized trials) reproduces the OR 1.62 migration→independence link and the OR ~3.8 <60-minute migration signal, then “tenecteplase + fast puncture” is no longer a preference but an evidence-based workflow mandate.

Best Combination

Stack this against the existing corpus on the same question. The ETLAS-2 and T-FLAVOR papers (already covered here) established tenecteplase’s non-inferiority/superiority profile for large-vessel occlusion and for bridging respectively — this paper supplies the why: the pharmacodynamic mechanism (early lytic peak, faster migration) that explains those outcome differences, plus the previously unexplained observation that tenecteplase’s benefit concentrates early after administration. Coupled with the AcT secondary analysis (which showed higher tenecteplase-driven pre-EVT recanalization) and the authors’ own prior work on 1-hour recanalization, the literature now triangulates on a coherent story: tenecteplase’s advantage is a rate advantage in the first hour, and the clinical benefit is realized only if the system converts fast lysis into fast thrombectomy. Read together, they argue the field should stop asking whether to bridge and start measuring IVT-to-puncture as the key modifiable variable.

Overvalue Warning

Two things a reader will overinterpret. First, do not treat this as randomized proof that tenecteplase beats alteplase for bridging. It is a well-matched but retrospective cohort; the overall functional-independence OR (1.43) has a confidence interval that bottoms out near 1.04, and the definitive randomized bridging evidence still comes from the ongoing trial this study references. Second, do not conflate migration with recanalization success. Migration nearly halved complete mTICI 3 reperfusion, and 39 of 114 migrants involved technical failure — the net benefit is real but it is a reperfusion-quality trade-off that only looks favorable because early reperfusion saved penumbra. A reader who walks away with “tenecteplase migrates clots, therefore it’s better, full stop” has missed that the benefit is conditional on capturing that first hour — and could misapply it to systems with long door-to-puncture delays, where the advantage likely evaporates.